 <h1>Regadenoson Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to regadenoson: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, regadenoson may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking regadenoson:</p><p>
<i>More common</i>
</p><ul>
<li>Arm, back, or jaw pain</li>
<li>chest pain or discomfort</li>
<li>difficult or labored breathing</li>
<li>fast or irregular heartbeat</li>
<li>nausea</li>
<li>sweating</li>
<li>tightness in the chest</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Confusion</li>
<li>difficulty swallowing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fainting</li>
<li>irregular heartbeat recurrent</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rash, hives, or itching skin</li>
<li>trembling or shaking of the hands or feet</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking regadenoson:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Dizziness</li>
<li>feeling of warmth</li>
<li>increased heart rate</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of regadenoson may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Headache</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Change in taste</li>
<li>loss of taste</li>
<li>stomach soreness or discomfort</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Diarrhea</li>
<li>difficulty with moving</li>
<li>joint pain</li>
<li>muscle aching or cramping</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to regadenoson: intravenous solution</i></p><h3>General</h3><p>The most common adverse reactions were dyspnea, headache, rhythm or conduction abnormalities, flushing, and rhythm abnormalities.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Rhythm or conduction abnormalities (26%), flushing (up to 23%), rhythm abnormalities (20%), ECG ST segment changes (18%), premature ventricular contractions (14%), angina pectoris or ST segment depression (12%)</p>
<p><b>Common</b> (1% to 10%): Premature atrial contractions, first degree atrioventricular (AV) block (PR prolongation greater than 220 msec), ventricular conduction abnormalities, decreased systolic blood pressure (greater than 35 mmHg), decreased diastolic blood pressure (greater than 25 mmHg), angina pectoris, AV block, tachycardia, palpitations, other ECG abnormalities including QTc prolongation, hypotension, ST to T depression of 2 mm or more</p>
<p><b>Uncommon</b> (0.1% to 1%): Second degree AV block, AV conduction abnormalities other than AV block, cardiac arrest, myocardial infarction, complete AV block, bradycardia, atrial flutter, atrial fibrillation (new-onset, worsening, or recurrent), hypertension, pallor, peripheral coldness, increased systolic blood pressure (50 mmHg or more), increased diastolic blood pressure (30 mmHg or more), ST to T elevation of 1 mm or more, acute coronary syndrome</p>
<p><b>Postmarketing reports</b>: Ventricular arrhythmias, supraventricular tachyarrhythmias, asystole, marked hypertension, symptomatic hypotension<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Pre-specified respiratory adverse reactions included dyspnea, wheezing, obstructive airway disorder, dyspnea exertional, and tachypnea.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Dyspnea (up to 29%), pre-specified respiratory adverse reaction (up to 19%)</p>
<p><b>Common</b> (1% to 10%): Wheezing, throat tightness, throat irritation, cough</p>
<p><b>Uncommon</b> (0.1% to 1%): Tachypnea</p>
<p><b>Postmarketing reports</b>: Respiratory arrest, respiratory distress, oxygen saturation decreased<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (27%), dizziness (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Dysgeusia, paresthesia, hypoesthesia, severe headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Convulsions, syncope, transient ischemic attack, unresponsiveness to stimuli, depressed level of consciousness, tremor, somnolence, tinnitus</p>
<p><b>Rare</b> (less than 0.1%): Cerebrovascular accident</p>
<p><b>Postmarketing reports</b>: Intracranial hemorrhage<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Chest pain (up to 19%), chest discomfort (13%)</p>
<p><b>Common</b> (1% to 10%): Malaise, asthenia</p>
<p><b>Uncommon</b> (0.1% to 1%): General body pain<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Gastrointestinal discomfort (15%)</p>
<p><b>Common</b> (1% to 10%): Nausea, abdominal discomfort, vomiting, oral discomfort</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal distention, diarrhea, fecal incontinence</p>
<p><b>Postmarketing reports</b>: Abdominal pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back or neck or jaw pain, pain in extremity, musculoskeletal discomfort</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Hyperhidrosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Angioedema, urticaria, rash, erythema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision blurred, eye pain<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Anxiety, insomnia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Pain at injection site<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Lexiscan (regadenoson)." Astellas Pharma US, Inc, Deerfield, IL. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about regadenoson</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>26 Reviews</li>
<li>Drug class: cardiac stressing agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Regadenoson Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Lexiscan</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diagnosis and Investigation</li>
<li>Radionuclide Myocardial Perfusion Study</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to regadenoson: intravenous solution</i></p><h3>General</h3><p>The most common adverse reactions were dyspnea, headache, rhythm or conduction abnormalities, flushing, and rhythm abnormalities.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Rhythm or conduction abnormalities (26%), flushing (up to 23%), rhythm abnormalities (20%), ECG ST segment changes (18%), premature ventricular contractions (14%), angina pectoris or ST segment depression (12%)</p><p><b>Common</b> (1% to 10%): Premature atrial contractions, first degree atrioventricular (AV) block (PR prolongation greater than 220 msec), ventricular conduction abnormalities, decreased systolic blood pressure (greater than 35 mmHg), decreased diastolic blood pressure (greater than 25 mmHg), angina pectoris, AV block, tachycardia, palpitations, other ECG abnormalities including QTc prolongation, hypotension, ST to T depression of 2 mm or more</p><p><b>Uncommon</b> (0.1% to 1%): Second degree AV block, AV conduction abnormalities other than AV block, cardiac arrest, myocardial infarction, complete AV block, bradycardia, atrial flutter, atrial fibrillation (new-onset, worsening, or recurrent), hypertension, pallor, peripheral coldness, increased systolic blood pressure (50 mmHg or more), increased diastolic blood pressure (30 mmHg or more), ST to T elevation of 1 mm or more, acute coronary syndrome</p><p><b>Postmarketing reports</b>: Ventricular arrhythmias, supraventricular tachyarrhythmias, asystole, marked hypertension, symptomatic hypotension<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Pre-specified respiratory adverse reactions included dyspnea, wheezing, obstructive airway disorder, dyspnea exertional, and tachypnea.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Dyspnea (up to 29%), pre-specified respiratory adverse reaction (up to 19%)</p><p><b>Common</b> (1% to 10%): Wheezing, throat tightness, throat irritation, cough</p><p><b>Uncommon</b> (0.1% to 1%): Tachypnea</p><p><b>Postmarketing reports</b>: Respiratory arrest, respiratory distress, oxygen saturation decreased<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (27%), dizziness (up to 11%)</p><p><b>Common</b> (1% to 10%): Dysgeusia, paresthesia, hypoesthesia, severe headache</p><p><b>Uncommon</b> (0.1% to 1%): Convulsions, syncope, transient ischemic attack, unresponsiveness to stimuli, depressed level of consciousness, tremor, somnolence, tinnitus</p><p><b>Rare</b> (less than 0.1%): Cerebrovascular accident</p><p><b>Postmarketing reports</b>: Intracranial hemorrhage<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Chest pain (up to 19%), chest discomfort (13%)</p><p><b>Common</b> (1% to 10%): Malaise, asthenia</p><p><b>Uncommon</b> (0.1% to 1%): General body pain<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Gastrointestinal discomfort (15%)</p><p><b>Common</b> (1% to 10%): Nausea, abdominal discomfort, vomiting, oral discomfort</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal distention, diarrhea, fecal incontinence</p><p><b>Postmarketing reports</b>: Abdominal pain<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back or neck or jaw pain, pain in extremity, musculoskeletal discomfort</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Hyperhidrosis</p><p><b>Uncommon</b> (0.1% to 1%): Angioedema, urticaria, rash, erythema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Vision blurred, eye pain<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Anxiety, insomnia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Anaphylaxis<sup>[Ref]</sup></p><h3>Local</h3><p><b>Uncommon</b> (0.1% to 1%): Pain at injection site<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Lexiscan (regadenoson)." Astellas Pharma US, Inc, Deerfield, IL. </p><h2>More about regadenoson</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>26 Reviews</li>
<li>Drug class: cardiac stressing agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Regadenoson Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diagnosis and Investigation</li>
<li>Radionuclide Myocardial Perfusion Study</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>